Fig 1
From: The burden of illness in Lennox–Gastaut syndrome: a systematic literature review
Timeline to show A the history of the characterization and treatment of LGS B the triad of symptoms characteristic of LGS and the clinical implications of the characterization of the syndrome. From: Lennox et al (1950) [1], Gastraut et al (1966) [2], Niedermeyer (1969) [90], Beaumanoir (1985) [91], ILAE 1989 [92], Engel (2001) [93], Arzimanoglou et al (2009) [3], Scheffer (2017) [94], World Health Organization (ICD-11) (2022) [64]. CLB, clobazam; CBD, cannabidiol; EEG, electroencephalogram; FFA, fenfluramine; FLB, felbamate; ILAE, International League Against Epilepsy; LGS, Lennox–Gastaut syndrome; LTG, lamotrigine; RUF, rufinamide; TPM, topiramate